Paper Details

  1. Home
  2. Paper Details

Acute myeloid leukemia transformed to a targetable disease.

Author: Khalifeh-SalehNadine, KourieHampig Raphael, SalehKhalil

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Acute myeloid leukemia (AML) is now considered a targetable disease with several new drugs approved. Gemtuzumab ozogamicin targets CD33+ AML, while midostaurin, gilteritinib, and crenolanib inhibit FLT3-positive AML. Ivosidenib and enasidenib are effective against IDH-mutated AML. These drugs have significantly changed the landscape of AML treatment.
Paper Details　
Original Abstract of the Article :
Acute myeloid leukemia (AML) is a heterogeneous neoplasm characterized by the monoclonal proliferation of immature progenitors. It is the most common acute leukemia in adults and its incidence increases with age. The standard traditional treatment in fit patients was the '3 + 7' regimen and cytarabi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2217/fon-2019-0670

データ提供：米国国立医学図書館（NLM）

AML: From Desert to Oasis

Acute myeloid leukemia (AML) is a serious blood cancer, like a relentless sandstorm, that can quickly overwhelm the body. This research explores the evolving landscape of AML treatment, highlighting the emergence of targeted therapies. The authors discuss the traditional treatment methods and the recent advancements in targeted therapies, such as gemtuzumab ozogamicin, midostaurin, gilteritinib, crenolanib, ivosidenib, and enasidenib. These new drugs are like oases in the desert, offering new hope for patients with AML.

A New Dawn in AML Treatment

The development of these targeted therapies has transformed AML from a formidable disease to a more manageable condition. It's like finding a hidden spring in the desert, bringing life and hope to a previously arid landscape. The authors discuss the mechanisms of action of these new drugs and the clinical trials that have led to their approval.

AML: A Journey Through the Desert

This research highlights the ongoing efforts to improve the treatment of AML. The development of new drugs is like finding new paths through the desert, offering hope for a future where AML is no longer a death sentence. It's a testament to the resilience and determination of researchers in their quest for better therapies.

Dr. Camel's Conclusion

The landscape of AML treatment has undergone a dramatic transformation, moving from the harsh desert of limited options to a more promising oasis of targeted therapies. This research is a beacon of hope, highlighting the potential for a future where AML is no longer a daunting foe.

Date :
  1. Date Completed 2021-02-08
  2. Date Revised 2021-02-08
Further Info :

Pubmed ID

32297538

DOI: Digital Object Identifier

10.2217/fon-2019-0670

Related Literature

Article Analysis
・Effects of quizartinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.